These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
14. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis]. Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033 [No Abstract] [Full Text] [Related]
15. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549 [TBL] [Abstract][Full Text] [Related]
16. Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a). Tindall AM; Kris-Etherton PM; Petersen KS J Nutr; 2020 Apr; 150(4):818-825. PubMed ID: 31909809 [TBL] [Abstract][Full Text] [Related]
17. Effects of lipoprotein apheresis on PCSK9 levels. Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324 [TBL] [Abstract][Full Text] [Related]
18. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Simonen P; Stenman UH; Gylling H Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271 [TBL] [Abstract][Full Text] [Related]
19. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Filippatos TD; Kei A; Rizos CV; Elisaf MS J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K Circ J; 2016; 80(2):512-8. PubMed ID: 26632531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]